PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more
PENTIXAPHARM HOLDING N AG (PTP) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PENTIXAPHARM HOLDING N AG - Net Assets Trend (None–None)
This chart illustrates how PENTIXAPHARM HOLDING N AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PENTIXAPHARM HOLDING N AG (None–None)
The table below shows the annual net assets of PENTIXAPHARM HOLDING N AG from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PENTIXAPHARM HOLDING N AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PENTIXAPHARM HOLDING N AG Competitors by Market Cap
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korchip
KQ:126730
|
$29.82 Million |
|
Stellar Resources Limited
PINK:SLROF
|
$29.82 Million |
|
MAG Holdings Berhad
KLSE:0095
|
$29.82 Million |
|
HRS Co. Ltd
KQ:036640
|
$29.83 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
$29.80 Million |
|
Siam Pan Group PCL
BK:SPG
|
$29.79 Million |
|
Scilex Holding Company
NASDAQ:SCLX
|
$29.79 Million |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
$29.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PENTIXAPHARM HOLDING N AG's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PENTIXAPHARM HOLDING N AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PENTIXAPHARM HOLDING N AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PENTIXAPHARM HOLDING N AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PENTIXAPHARM HOLDING N AG (PTP) | €- | N/A | N/A | $29.81 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |